340B Hospital Study Fuels Debate On Motives Behind Program Expansion
This article was originally published in The Pink Sheet Daily
Executive Summary
A study published in Health Affairs finds that 340B hospitals and affiliated clinics registered in recent years have been in wealthier communities than previously. The authors believe the results support manufacturers’ allegation that the drug discount program is migrating to “one that enriches hospitals and their affiliated clinics.”
You may also be interested in...
340B Lobby Group Seeks Bill Changing Hospital Eligibility For Discount Drugs
A group supported by drug manufacturers and pharmacy benefit managers – the Alliance for Integrity and Reform of 340B – is pushing Congress to alter how hospitals qualify for discounted drugs under the 340B program.
Gaming 340B: Sen. Grassley Wants Answers On How A Hospital Bends Drug Discount Rules
The ranking member on the Senate Judiciary Committee sends a letter to the University of Alabama Hospital seeking details on how it has changed the admission status and treatment of patients to get 340B drug discounts for patients who would not have been eligible otherwise.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.